Harmony Sciences shares plunged Wednesday after the FDA rejected its bread-and-butter drug as a treatment for a daytime sleepiness condition.

Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a ...

Harmony Biosciences Holdings, Inc. today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive ...

Harmony Biosciences' ( NASDAQ: HRMY) stock fell about 7.3% after U.S. FDA notified the company that it will not review the ...

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

An expert discusses treatments for narcolepsy, comparing options for managing excessive daytime sleepiness (EDS) and cataplexy, and examines the advantages, limitations, and clinical scenarios for ...

A multiple sleep latency test (MSLT) is an objective way to measure sleep quality. It helps diagnose narcolepsy and insomnia.

An expert discusses how key symptoms of narcolepsy, such as excessive daytime sleepiness and cataplexy, impact daily functioning and quality of life, along with the primary differences between type 1 ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

It warns: "You need to tell DVLA about some medical conditions as they can affect your driving. You can be fined up to £1,000 if you do not tell DVLA about a medical condition that affects your ...